Drug development for cancer chemoprevention: Focus on molecular targets

Seminars in Oncology

Volumn 37, Issue 4, 2010, Pages 345-358

  Johnson, Karen A ^a   Brown, Powel H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; BICALUTAMIDE; CAPECITABINE; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DUTASTERIDE; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FINASTERIDE; FLUTAMIDE; FULVESTRANT; GEFITINIB; GONADORELIN DERIVATIVE; LAPATINIB; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PANITUMUMAB; PROSTAGLANDIN E2; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ADENOMATOUS POLYP; ADVANCED CANCER; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CELL SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DNA REPAIR; DRUG SCREENING; DRUG TARGETING; ENZYME BINDING; EPITHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; INTRADUCTAL CARCINOMA; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; OSTEOPOROSIS; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK; RISK REDUCTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG DESIGN; METABOLISM; NEOPLASMS;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 77956369648     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.05.012     Document Type: Article

References (112)

1. B.J. Druker, and A. David Karnofsky Award lecture Imatinib as a paradigm of targeted therapies J Clin Oncol 21 2003 239s 245s
2. S.L. Nightingale From the FDA JAMA 255 1986 1836
3. C.L. Vogel Phase II and III clinical trials of toremifene for metastatic breast cancer Oncology (Williston Park) 12 1998 9 13
4. P.F. Bross, A. Baird, and G. Chen Fulvestrant in postmenopausal women with advanced breast cancer Clin Cancer Res 9 2003 4309 4317
5. B.J. Roseman, A.U. Buzdar, and S.E. Singletary Use of aromatase inhibitors in postmenopausal women with advanced breast cancer J Surg Oncol 66 1997 215 220
6. M.H. Cohen, J.R. Johnson, N. Li, G. Chen, and R. Pazdur Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer Clin Cancer Res 8 2002 665 669
7. P. Lombardi Exemestane, a new steroidal aromatase inhibitor of clinical relevance Biochim Biophys Acta 1587 2002 326 337
8. W.M. Wong Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer Cancer Pract 7 1999 48 50
9. B. Moy, P. Kirkpatrick, S. Kar, and P. Goss Lapatinib Nat Rev Drug Discov 6 2007 431 432
10. B.R. Goldspiel, and D.R. Kohler Flutamide: an antiandrogen for advanced prostate cancer Drug Intell Clin Pharm 24 1990 616 623
11. G.J. Kolvenbag, G.R. Blackledge, and K. Gotting-Smith Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development Prostate 34 1998 61 72
12. J. Graham, M. Muhsin, and P. Kirkpatrick Cetuximab Nat Rev Drug Discov 3 2004 549 550
13. R.M. Giusti, M.H. Cohen, P. Keegan, and R. Pazdur FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer Oncologist 14 2009 284 290
14. M. Muhsin, J. Graham, and P. Kirkpatrick Gefitinib Nat Rev Drug Discov 2 2003 515 516
15. A. Kim, F.M. Balis, and B.C. Widemann Sorafenib and sunitinib Oncologist 14 2009 800 805
16. B. Rini, S. Kar, and P. Kirkpatrick Temsirolimus Nat Rev Drug Discov 6 2007 599 600
17. M.B. Atkins, U. Yasothan, and P. Kirkpatrick Everolimus Nat Rev Drug Discov 8 2009 535 536
18. C.K. Osborne Steroid hormone receptors in breast cancer management Breast Cancer Res Treat 51 1998 227 238
19. J.P. Lewis The Breast Cancer Continuum: insights from the tamoxifen trials impact future drug development strategies Ann N Y Acad Sci 949 2001 327 332
20. J. Cuzick, and M. Baum Tamoxifen and contralateral breast cancer Lancet 2 1985 282
21. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
22. E. Tan-Chiu, J. Wang, and J.P. Costantino Effects of tamoxifen on benign breast disease in women at high risk for breast cancer J Natl Cancer Inst 95 2003 302 307
23. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 2005 1652 1662
24. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial Multiple Outcomes of Raloxifene Evaluation JAMA 281 1999 2189 2197
25. S. Martino, J.A. Cauley, and E. Barrett-Connor Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 2004 1751 1761
26. E. Barrett-Connor, L. Mosca, and P. Collins Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2006 125 137
27. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
28. B.P. Haynes, M. Dowsett, W.R. Miller, J.M. Dixon, and A.S. Bhatnagar The pharmacology of letrozole J Steroid Biochem Mol Biol 87 2003 35 45
29. H. Sasano, Y. Miki, R. Shibuya, and T. Suzuki Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast J Steroid Biochem Mol Biol 118 2010 242 245
30. Y. Hong, H. Li, and J. Ye Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity PLoS One 4 2009 e8050
31. R.W. Brueggemeier Update on the use of aromatase inhibitors in breast cancer Expert Opin Pharmacother 7 2006 1919 1930
32. B.P. Haynes, A.H. Straume, and J. Geisler Intratumoral estrogen disposition in breast cancer Clin Cancer Res 16 2010 1790 1801
33. A.E. Lykkesfeldt, K.L. Henriksen, and B.B. Rasmussen In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer BMC Cancer 9 2009 185
34. K. Takagi, Y. Miki, and S. Nagasaki Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment Endocr Relat Cancer 17 2010 415 430
35. A. Howell, J. Cuzick, and M. Baum Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
36. A.S. Coates, A. Keshaviah, and B. Thurlimann Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 2007 486 492
37. J. Cuzick IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole Expert Rev Anticancer Ther 8 2008 1377 1385
38. H. Richardson, D. Johnston, J. Pater, P. Goss The National Cancer Institute of Canada Clinical Trials Group MAP 3 trial: an international breast cancer prevention trial Curr Oncol 14 2007 89 96
39. A. Howell The endocrine prevention of breast cancer Best Pract Res Clin Endocrinol Metab 22 2008 615 623
40. J.A. Richards, and R.W. Brueggemeier Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes J Clin Endocrinol Metab 88 2003 2810 2816
41. R.W. Brueggemeier, E.S. Diaz-Cruz, P.K. Li, Y. Sugimoto, Y.C. Lin, and C.L. Shapiro Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer J Steroid Biochem Mol Biol 95 2005 129 136
42. B. Takkouche, C. Regueira-Mendez, and M. Etminan Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis J Natl Cancer Inst 100 2008 1439 1447
43. O.W. Brawley, and I.M. Thompson Chemoprevention of prostate cancer Urology 43 1994 594 599
44. C.L. Foley, and R.S. Kirby 5 alpha-reductase inhibitors: what's new? Curr Opin Urol 13 2003 31 37
45. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
46. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
47. A. Rostom, C. Dube, and G. Lewin Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force Ann Intern Med 146 2007 376 389
48. S. Gill, and F.A. Sinicrope Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol 32 2005 24 34
49. M. Hayden, M. Pignone, C. Phillips, and C. Mulrow Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 136 2002 161 172
50. T. Wolff, T. Miller, and S. Ko Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 150 2009 405 410
51. P.H. Gann, J.E. Manson, R.J. Glynn, J.E. Buring, and C.H. Hennekens Low-dose aspirin and incidence of colorectal tumors in a randomized trial J Natl Cancer Inst 85 1993 1220 1224
52. N.R. Cook, I.M. Lee, and J.M. Gaziano Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial JAMA 294 2005 47 55
53. R.S. Sandler Point/Counterpoint: aspirin should not be promoted for colon cancer prevention: counterpoint Cancer Epidemiol Biomarkers Prev 17 2008 1562 1563
54. M.M. Bertagnolli, C.J. Eagle, and A.G. Zauber Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 2006 873 884
55. N. Arber, C.J. Eagle, and J. Spicak Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 2006 885 895
56. J.A. Baron, R.S. Sandler, and R.S. Bresalier A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 2006 1674 1682
57. G. Steinbach, P.M. Lynch, and R.K. Phillips The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
58. F.L. Meyskens Jr, C.E. McLaren, and D. Pelot Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prev Res (Phila Pa) 1 2008 32 38
59. E.W. Gerner, F.L. Meyskens Jr, S. Goldschmid, P. Lance, and D. Pelot Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention Amino Acids 33 2007 189 195
60. N. Babbar, E.W. Gerner, and R.A. Casero Jr Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells Biochem J 394 2006 317 324
61. P.J. Allen The management of intraductal papillary mucinous neoplasms of the pancreas Surg Oncol Clin N Am 19 2010 297 310
62. W.N. William Jr, J.V. Heymach, E.S. Kim, and S.M. Lippman Molecular targets for cancer chemoprevention Nat Rev Drug Discov 8 2009 213 225
63. L. Mao, J.S. Lee, and Y.H. Fan Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment Nat Med 2 1996 682 685
64. M. Srinivasan, and S.D. Jewell Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry Oncology 61 2001 284 292
65. M. Salaun, R. Sesboue, and S. Moreno-Swirc Molecular predictive factors for progression of high-grade preinvasive bronchial lesions Am J Respir Crit Care Med 177 2008 880 886
66. B.J. Reid, X. Li, P.C. Galipeau, and T.L. Vaughan Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis Nat Rev Cancer 10 2010 87 101
67. Y. Li, J.M. Wo, M.B. Ray, W. Jones, R.R. Su, and S. Ellis Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma World J Gastroenterol 12 2006 928 934
68. S. Jain, S. Singhal, P. Lee, and R. Xu Molecular genetics of hepatocellular neoplasia Am J Transl Res 2 2010 105 118
69. O. Strobel, D.E. Rosow, and E.Y. Rakhlin Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia Gastroenterology 138 2010 1166 1177
70. S. Liu, C. Ginestier, and E. Charafe-Jauffret BRCA1 regulates human mammary stem/progenitor cell fate Proc Natl Acad Sci U S A 105 2008 1680 1685
71. M. Kakarala, D.E. Brenner, and H. Korkaya Targeting breast stem cells with the cancer preventive compounds curcumin and piperine Breast Cancer Res Treat 2009 Epub ahead of print
72. E. Jarboe, A. Folkins, and M.R. Nucci Serous carcinogenesis in the fallopian tube: a descriptive classification Int J Gynecol Pathol 27 2008 1 9
73. C.P. Crum, R. Drapkin, and A. Miron The distal fallopian tube: a new model for pelvic serous carcinogenesis Curr Opin Obstet Gynecol 19 2007 3 9
74. T. Walsh, and M.C. King Ten genes for inherited breast cancer Cancer Cell 11 2007 103 105
75. N. McCabe, N.C. Turner, and C.J. Lord Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 2006 8109 8115
76. H. Farmer, N. McCabe, and C.J. Lord Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
77. S. Kummar, R. Kinders, and M.E. Gutierrez Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies J Clin Oncol 27 2009 2705 2711
78. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
79. L. Wang, I.M. Lee, S.M. Zhang, J.B. Blumberg, J.E. Buring, and H.D. Sesso Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women Am J Clin Nutr 89 2009 905 912
80. G.J. Kelloff, J.R. Johnson, and J.A. Crowell Approaches to the development and marketing approval of drugs that prevent cancer Cancer Epidemiol Biomarkers Prev 4 1995 1 10
81. J.S. Lee, I.S. Chu, and A. Mikaelyan Application of comparative functional genomics to identify best-fit mouse models to study human cancer Nat Genet 36 2004 1306 1311
82. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci U S A 98 2001 5116 5121
83. A. Subramanian, P. Tamayo, and V.K. Mootha Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci U S A 102 2005 15545 15550
84. J.I. Herschkowitz, K. Simin, and V.J. Weigman Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors Genome Biol 8 2007 R76
85. S. Kaiser, Y.K. Park, and J.L. Franklin Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer Genome Biol 8 2007 R131
86. A.C. Borczuk, L. Gorenstein, K.L. Walter, A.A. Assaad, L. Wang, and C.A. Powell Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways Am J Pathol 163 2003 1949 1960
87. M.H. Cohen, J.R. Johnson, Y.F. Chen, R. Sridhara, and R. Pazdur FDA drug approval summary: erlotinib (Tarceva) tablets Oncologist 10 2005 461 466
88. T. Matsunaga, S. Endo, and M. Soda Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis Biochem Biophys Res Commun 389 2009 128 132
89. P.M. Luthra, R. Kumar, and A. Prakash Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells Biochem Biophys Res Commun 384 2009 420 425
90. J. Jankun, A.M. Aleem, and S. Malgorzewicz Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells Mol Cancer Ther 5 2006 1371 1382
91. A.B. Kunnumakkara, P. Anand, and B.B. Aggarwal Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins Cancer Lett 269 2008 199 225
92. R. Artali, G. Beretta, P. Morazzoni, E. Bombardelli, and F. Meneghetti Green tea catechins in chemoprevention of cancer: a molecular docking investigation into their interaction with glutathione S-transferase (GST P1-1) J Enzyme Inhib Med Chem 24 2009 287 295
93. D. Chen, C.Y. Wang, J.D. Lambert, N. Ai, W.J. Welsh, and C.S. Yang Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies Biochem Pharmacol 69 2005 1523 1531
94. W.J. Lee, J.Y. Shim, and B.T. Zhu Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids Mol Pharmacol 68 2005 1018 1030
95. T. Kuzuhara, Y. Sei, K. Yamaguchi, M. Suganuma, and H. Fujiki DNA and RNA as new binding targets of green tea catechins J Biol Chem 281 2006 17446 17456
96. D. Chen, V. Milacic, and M.S. Chen Tea polyphenols, their biological effects and potential molecular targets Histol Histopathol 23 2008 487 496
97. K. Boehm, F. Borrelli, and E. Ernst Green tea (Camellia sinensis) for the prevention of cancer Cochrane Database Syst Rev 2009 CD005004
98. G.G. Kuiper, J.G. Lemmen, and B. Carlsson Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta Endocrinology 139 1998 4252 4263
99. M.A. Neves, T.C. Dinis, G. Colombo, and M.L. Sa e Melo Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols ChemMedChem 2 2007 1750 1762
100. L. Xu, Y. Ding, and W.J. Catalona MEK4 function, genistein treatment, and invasion of human prostate cancer cells J Natl Cancer Inst 101 2009 1141 1155
101. S. Banerjee, Y. Li, Z. Wang, and F.H. Sarkar Multi-targeted therapy of cancer by genistein Cancer Lett 269 2008 226 242
102. S. Safe Molecular biology of the Ah receptor and its role in carcinogenesis Toxicol Lett 120 2001 1 7
103. B.S. Cornblatt, L. Ye, and A.T. Dinkova-Kostova Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast Carcinogenesis 28 2007 1485 1490
104. J.L. Bowers, V.V. Tyulmenkov, S.C. Jernigan, and C.M. Klinge Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta Endocrinology 141 2000 3657 3667
105. L. Buryanovskyy, Y. Fu, and M. Boyd Crystal structure of quinone reductase 2 in complex with resveratrol Biochemistry 43 2004 11417 11426
106. P. de Medina, R. Casper, J.F. Savouret, and M. Poirot Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators J Med Chem 48 2005 287 291
107. C. Pinto Mdel, and P. Macias Oxidation of dietary polyphenolics by hydroperoxidase activity of lipoxygenase J Agric Food Chem 53 2005 9225 9230
108. K.T. Howitz, K.J. Bitterman, and H.Y. Cohen Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 2003 191 196
109. D.A. Sallman, X. Chen, and B. Zhong Clusterin mediates TRAIL resistance in prostate tumor cells Mol Cancer Ther 6 2007 2938 2947
110. B. Lomenick, R. Hao, and N. Jonai Target identification using drug affinity responsive target stability (DARTS) Proc Natl Acad Sci U S A 106 2009 21984 21989
111. J.A. Baur, and D.A. Sinclair Therapeutic potential of resveratrol: the in vivo evidence Nat Rev Drug Discov 5 2006 493 506
112. M. Athar, J.H. Back, L. Kopelovich, D.R. Bickers, and A.L. Kim Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms Arch Biochem Biophys 486 2009 95 102